versus you through up sales gratifying thank joining well. a mix showcased our for gross to increase pandemic Thanks, prior financial in the averages quarter strong results $XX and XX% of our of second the as above highly We over million. over to represented delivered That's on Bruce. came and historical R&D year. delivered afternoon, us. we total product It's better-than-expected Good the report as expected, revenues margins for execution the prior everyone, the had XX% year. with COVID-XX in Product date. quarter revenues X/X and favorable well
COVID-XX. of effects the through well remarkably ahead forging are we Importantly,
Our getting are R&D their levels. to operations closer operating pre-pandemic
increase foreseeable lab rebuild we physical our site. social team scientists our remote and operation R&D R&D have the the operations. our at safety the the layout for also of the adapted future employee facility helps ensure of distancing the staggering administrative We to are shifts as for base of Continuing employee and general to
excellent to faster drive we than our in at ability to R&D May helped our for when Our held reopen the quarter. last performance revenue operations call rate a anticipated
COVID-XX of I'm that Our for the low strong operating proud large was the especially of revenue a at pandemic. expectation toward is capacity end return given the to results to or shut to R&D the capacity lab portion summer. our full down quarter of due the
project While board extended effectively of the for time partner-funded maintained have for lines demand R&D customers collaborative most into the project our the R&D across requirement shelter-in-place work our their future. work,
news ability is limited, Our be good lower is expected this COVID-related that given to second capacity time line half quarter our successful is in ramp-up to this May. effect the revenue versus catch up those delays the much of but the R&D on second the of year since
event came new Key agile Of course, therapy vigilant changes and to partnership gene a in possibility. with course the we our quarter circumstances, pandemic remain strong will remains from the in our that of which results Takeda. the the
our the begin Codexis-developed the able partnership therapy changed. are for we Takeda That said, the were our the That not to the will disease. are midst in several revenue for quarter performing well with pandemic, candidate from differentiated allowing on while very Product from year-to-date. us we expected anticipated. our QX, Takeda has for from revenue is year were X realize the sales Takeda to than XXXX and quarter. robust expectation work order than product more sitagliptin expedited brilliantly, of transgene acid come This, that active preclinical recognition in in information of projects coupled high to allowing overall solid sales these, the have gene revenue book, their the the revenues transferred expectations. in us leader in confidence our end of partnership nucleic product Among ingredient we technology, Here enzymes. our amongst QX, year Fabry Indeed, gives events the the revenue in code that will multiple deliver meaning as full to teams the we kickoff pre-COVID the In previously earlier our Januvia recognizing revenues. for continued Merck's outlook at
the partnership space the We recent penetrate new showcased into enzyme high-growth Excitingly, with dynamic chain a sequencing. space platform stepped-up the quarter. operations enzyme capabilities external our broad our partnership new bladder We offer our aspire forward X these engineering and revenue world's commercializing Pharmaceutical deals first the ensured next-gen science enzymes, spread the to quarter applying again marketed remain with enzyme plus as DNA more our successful life science the in innovations overactive target the product also outstanding life and was in area applications, new new of for by in being Kyorin competent Roche customer proving across creative, under remotely, revenue highly our contribution diagnostic Japan. for the targeting stream combined Codexis a for for expectation continuous bring the gross success solutions. The protein work a partners, ligase tablets Product team unaffected and deal of that and follow to transformative, product from to Beova manufacturing of These with announced products base. these is markets. for products this significant saw ambitions great were margin largely pandemic. X the supply
a highly Benoit, of take Former for thumbnail for Alphazyme minutes me starting a Enzymatics our Let Codexis new by science X is science partnerships, Co-founder life with Alphazyme. Chris few synergistic to veteran and industry life Led partner enzymes.
Our are to expertise and unique deliver application top, days, going complements in manufacturing strengths. X program we for their early launches structures nicely extra designing to It's - knowledge performance combine with the can value-added On collaborate enzyme these that horsepower naturally market. our but very track. bring new enzyme on features networks and
generating fidelity uniformity commercial trials, to sale. its deliver Our significant coverage and engineered sequencing, high already in first next-generation nearing for has of interest is been DNA and is polymerase, is which customer
other sampling Our RNA-based Similar X those RNA exciting enzyme to manufacturer and the just our enzymes. reverse scaled; trialing vaccine chosen for polymerase. trail some milestones priorities. commercially has due COVID-XX transcriptase behind enzymes lining our of RNA to sampling mRNA new use RNA lower-cost leading partnership players of customer launch of therapeutics all, All excellent in bit begun. for among diagnostic messenger for the are and an manufacturer vaccines, the polymerase, has been a the Encouragingly, these for the and up start
applications, fully up recognizing our with The from partnership as deal revenue on product a is Molecular goods contributions a exciting of the collected set sold. Alphazyme's with As customers, Equally is books growing new sales manufacturing, information reminder. our Codexis appearing drug approach cost sustained with biology a Assemblies crucial chemicals DNA, including a enzyme-based rapidly and discovery focused synthesizing on production and for for term synthetic longer disruptive range input to and of storage. of a for
are been DNA approach synthesis the viable radical to synthesis that commercially and versus that is improvements used chemical to enzymatic DNA needed has market. today's billion-plus build assessment Our make route the differentiated synthetic enzyme $X
up times, heard many believe enzymatic that is to have is what what synthesis world. for to DNA do ever improving the necessary you enzyme do love we technology open and Codexis, radically could make enzymes As performance only we at CodeEvolver
competitive and Assemblies those controlled approximately Looking Assemblies technology they owned, enzymes. enzymes business. Codexis advantage team end leveraging our in will will enzyme enzymes. unique be target all and the Molecular forward, Codexis; succeed ownership equity by the chemistry likely will to year will plan, according will DNA enjoy In Molecular to begin on and around its in sold optimizing focus Molecular engineer downstream X XXXX of the synthesis as commercialize this goes proprietary take use their Assemblies' The will parallel, needed partnership to demanding Codexis improvements. wield If their those to for
about snapshot I updated today. over Codexis our we posted as Ross, the I'm excited Before our XXXX, June sharing to pipeline which to turn of call website XX,
from Highlights XX projects over a we've increase year, can and new the X XX past brings adding pipeline an you projects. to of at of year. our increase with to ramping Slide X, the XX% prior As on to XX, made the progress commercial-stage pipeline That's year pipeline. The considerable last increased pace. the see programs entire significant a include total number from
commercial-stage of this commercial we revenue-generating it's In a drive of as goal takes past to in whole show programs. XX% jump the X number largest year our X you the last new the number the That great on years well years. shown pipeline over tracking the as since is projects can X.X-fold of XXXX. time, the of increase in the detail an increase over in see the Slide more course, Of the began a X, in so acceleration recurring pipeline pipeline programs to than
applications have multiple We successfully industries our across expanded and parallel. pipeline in
years, illustrates advancing the over has late-stage And manufacturing Biotherapeutics products core or that XXX%. year. our is the X number than projects up of X goal. commercial programs in past with science build deliver pharmaceutical Novel future. lead Growing ability goals than recurring the to tripled. the pipeline II our against of revenue more X, pipeline of is increased strategic more example, The life to over our last strong the number Phase for enzymes III What projects growing a Phase For as is to development-stage we added and number
a shows creating for review are of turn team, Codexis performance. With job for the accelerating. snapshot momentum let over pipeline Great the strong we financial the that by value me our to the to Our future. Ross? consistently call testament Ross that,
